trending Market Intelligence /marketintelligence/en/news-insights/trending/r1yymntvm_h__zuv1t9h2g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Novo Nordisk's Ozempic approved in Japan

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Novo Nordisk's Ozempic approved in Japan

The Japanese Ministry of Health, Labor and Welfare approved Novo Nordisk A/S' Ozempic to treat adults with type 2 diabetes.

The approval was based on results from the company's clinical trial program called Sustain, which enrolled more than 8,000 patients in five studies. Data showed that Ozempic reduced blood sugar levels better than comparator treatments and led to greater reductions in mean body weight compared to placebo.

Denmark-based Novo Nordisk plans to launch the drug in Japan within the coming months.

Ozempic is already approved in the U.S., Canada and the EU.